History of autologous platelet‐rich plasma: A short review

Mościcka, Patrycja; Przylipiak, Andrzej

doi:10.1111/jocd.14326

Cited by 21 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The origin of the therapy comes from transfusiology, where platelet concentrates are used to treat thrombocytopenia. 1 In 1954, for the first time, the term "platelet-rich-plasma" (PRP) was employed by Kingsley 2 (1954), when referring to platelet concentrates for transfusion. The first clinical demonstration that autologous platelet concentrates promoted healing when used locally was reported by Knighton, et al 3 (1986).…”

Section: History and Evolution Of Autologous Platelet Aggregates For ...mentioning

confidence: 99%

Autologous platelet concentrates for facial rejuvenation

Buzalaf

Levy

2022

J. Appl. Oral Sci.

View full text Add to dashboard Cite

Autologous platelet concentrates (APCs) are promising therapeutic agents in facial rejuvenation since they are a great source of cytokines, growth factors and other biologically active substances. Obtained from the patient's blood, they have the advantages of reducing immunological reactions, making the procedure safer, well tolerated, with minimal adverse effects and lower cost. Currently, they are used for facial rejuvenation both in combination with microneedling and in mesotherapy techniques, as well as to treat facial acne scars, melasma and wounds after laser ablative treatments. This review summarizes current knowledge on the use of APCs, ranging from basic concepts related to their composition and mechanisms of action to up-to-date information on their clinical efficacy. Methodology: MEDLINE (PubMed) was searched from inception through 2021 for English language publications on APCs for facial rejuvenation. Results: A total of 100 files were found. Based on the available literature, APCs for skin rejuvenation are safe and well tolerated.The most studied product is the first-generation material, platelet-rich plasma (PRP). Conclusions: The results are in general favorable, but the quality of the studies is low. The second and third generation products, platelet-rich fibrin (PRF) and injectable platelet-rich fibrin (i-PRF), respectively, are easier to be obtained and, at least in vitro, seem to induce greater collagen production than PRP, especially under lower relative centrifugation forces, but to date only a few clinical trials evaluating these products exist. More high-quality trials with appropriate follow-up are necessary to provide adequate evidence that may help to improve the treatment regimens with APCs. Many aspects should be considered when designing clinical trials to evaluate APCs, such as the patients' characteristics that best predict a favorable response, the optimal number of sessions and the interval between them, the characteristics of the studies and the development of better instruments to evaluate skin aging.

show abstract

Section: History and Evolution Of Autologous Platelet Aggregates For ...mentioning

confidence: 99%

Autologous platelet concentrates for facial rejuvenation

Buzalaf

Levy

2022

J. Appl. Oral Sci.

View full text Add to dashboard Cite

show abstract

“…A review of the literature shows that the history of various PRP-based therapies is at least 70 years old. For this reason, it is widely accepted that the method is sufficiently well-established to allow widespread use in medicine, particularly in sports medicine, and orthopedics [114]. The use of PRP in the process of plasmapheresis in enhancing bone regeneration was described in 1999 by Anitua [115,116].…”

Section: Platelet-rich Plasma (Prp)/platelet-rich Fibrin (Prf) As Second Line Treatmentmentioning

confidence: 99%

“…In sum, PRP is an autologous orthobiologic treatment option for musculoskeletal conditions with favorable results in a limited number of high-quality clinical trials. PRP therapy is currently used to treat degenerative disorders and promote the healing of tendons, ligaments, muscles, and cartilage [114].…”

Section: Platelet-rich Plasma (Prp)/platelet-rich Fibrin (Prf) As Second Line Treatmentmentioning

confidence: 99%

“…References Functions PDGF [114,[132][133][134][135][136][137] The first growth factor to be approved for the treatment of human ulcers; Plays a significant role in blood vessel formation (angiogenesis process); Enhances proliferation of fibroblasts and their effectiveness in the production of extracellular matrix; Regulates cell growth and division; Helps in tissue remodeling and cellular differentiation; Helps in mesenchymal proliferation and directs the migration and differentiation; Promotes the healing of wounds.…”

Section: Growth Factors/mentioning

confidence: 99%

See 1 more Smart Citation

Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment

Nowaczyk

Szwedowski

Dallo³

et al. 2022

IJMS

View full text Add to dashboard Cite

Osteoarthritis (OA) can be defined as the result of pathological processes of various etiologies leading to damage to the articular structures. Although the mechanism of degenerative changes has become better understood due to the plethora of biochemical and genetic studies, the drug that could stop the degenerative cascade is still unknown. All available forms of OA therapy are based on symptomatic treatment. According to actual guidelines, comprehensive treatment of OA should always include a combination of various therapeutic options aimed at common goals, which are pain relief in the first place, and then the improvement of function. Local treatment has become more common practice, which takes place between rehabilitation and pharmacological treatment in the hierarchy of procedures. Only in the case of no improvement and the presence of advanced lesions visible in imaging tests, should surgery be considered. Currently, an increasing number of studies are being published suggesting that intra-articular injections may be as effective or even more effective than non-steroidal anti-inflammatory drugs (NSAIDs) and result in fewer systemic adverse events. The most commonly used preparations are hyaluronic acid (HA), glucocorticosteroids (GS), and also platelet-rich plasma (PRP) in recent years. This review aims to present the mechanism of action and clinical effectiveness of different pharmacological options in relieving pain and improving functions in OA as well as the emerging approach in intra-articular treatment with PRP.

show abstract

“…Platelet-rich plasma is synonymous with plateletrich growth factors, platelet-rich fibrin matrix, and platelet concentrate and is used in the treatment of thrombocytopenia [22]. The extensive use of PRP for platelet transfusion in the treatment of thrombocytopenia resulted in an improvement in the platelet concentrate preparation techniques [24].…”

Section: Review History Of Prp Therapymentioning

confidence: 99%

Efficacy of Platelet-Rich Plasma Injection in the Management of Rotator Cuff Tendinopathy: A Review of the Current Literature

Bhan¹,

Singh²

2022

Cureus

View full text Add to dashboard Cite

Platelet-rich plasma (PRP) is being projected as a newer and superior treatment option for rotator cuff tendinopathy. With the first use of PRP in trauma and orthopedics dating back only to 1998, its advent into the field is relatively recent. Thus, data on long-term efficacy, large cohort studies, or large randomized controlled trials are fairly limited. Moreover, owing to the absence of standardized methods of platelet extraction and lack of consensus on the ideal concentration of platelets in PRP, data comparison from different studies is difficult. Things are complicated by the fact that it is also not clear whether a single injection of PRP is therapeutic or if multiple serial injections are needed to produce the desired effects. The literature on efficacy and pain relief is also obtained from studies with low sample sizes and short followups. The dropout rate and noncompliance rate were also found to be high in some studies. Thus, the data is often not clinically significant and may also be biased due to the non-standardized inclusion and exclusion criteria of the studies. Though multiple studies have suggested good pain control with PRP injection, many studies have found that PRP injection therapy may not be any better than the physical therapy regimen prescribed to patients with rotator cuff tendinopathy. Also, the data on the efficacy of PRP on shoulder function and shoulder range of motion is at variance. This submission aims to evaluate the efficacy and use of PRP in the management of rotator cuff tendinopathy.

show abstract

History of autologous platelet‐rich plasma: A short review

Cited by 21 publications

References 33 publications

Autologous platelet concentrates for facial rejuvenation

Autologous platelet concentrates for facial rejuvenation

Overview of First-Line and Second-Line Pharmacotherapies for Osteoarthritis with Special Focus on Intra-Articular Treatment

Efficacy of Platelet-Rich Plasma Injection in the Management of Rotator Cuff Tendinopathy: A Review of the Current Literature

Contact Info

Product

Resources

About